DK2053063T3 - Genkendelsesmolekyler til behandling og påvisning af tumorer - Google Patents

Genkendelsesmolekyler til behandling og påvisning af tumorer

Info

Publication number
DK2053063T3
DK2053063T3 DK08171923.9T DK08171923T DK2053063T3 DK 2053063 T3 DK2053063 T3 DK 2053063T3 DK 08171923 T DK08171923 T DK 08171923T DK 2053063 T3 DK2053063 T3 DK 2053063T3
Authority
DK
Denmark
Prior art keywords
tyr
asn
gly
ala
sequences
Prior art date
Application number
DK08171923.9T
Other languages
English (en)
Inventor
Steffen Goletz
Antje Danielczyk
Renate Stahn
Uwe Karsten
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Application granted granted Critical
Publication of DK2053063T3 publication Critical patent/DK2053063T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Finger-Pressure Massage (AREA)
DK08171923.9T 2003-01-23 2004-01-23 Genkendelsesmolekyler til behandling og påvisning af tumorer DK2053063T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10303664A DE10303664A1 (de) 2003-01-23 2003-01-23 Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
EP04704545A EP1585770B1 (de) 2003-01-23 2004-01-23 Erkennungsmoleküle zur behandlung und detektion von tumoren

Publications (1)

Publication Number Publication Date
DK2053063T3 true DK2053063T3 (da) 2013-09-30

Family

ID=32695061

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08171923.9T DK2053063T3 (da) 2003-01-23 2004-01-23 Genkendelsesmolekyler til behandling og påvisning af tumorer
DK04704545T DK1585770T3 (da) 2003-01-23 2004-01-23 Genkendelsesmolekyler til behandling og påvisning af tumorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04704545T DK1585770T3 (da) 2003-01-23 2004-01-23 Genkendelsesmolekyler til behandling og påvisning af tumorer

Country Status (10)

Country Link
US (2) US8779102B2 (da)
EP (2) EP2053063B1 (da)
AT (1) ATE421537T1 (da)
CY (2) CY1108965T1 (da)
DE (2) DE10303664A1 (da)
DK (2) DK2053063T3 (da)
ES (2) ES2427832T3 (da)
PT (2) PT1585770E (da)
SI (2) SI2053063T1 (da)
WO (1) WO2004065423A2 (da)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
DE10256900A1 (de) 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
ES2897506T3 (es) 2003-01-09 2022-03-01 Macrogenics Inc Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
DE10303664A1 (de) * 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
MXPA06012601A (es) 2004-05-10 2007-05-10 Macrogenics Inc Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos.
AU2006208226A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US9296816B2 (en) 2005-04-15 2016-03-29 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
GB2437727B (en) * 2006-05-04 2011-04-20 Univ Open Aptamers directed to MUC1
HUE030269T2 (en) 2006-06-26 2017-04-28 Macrogenics Inc FC RIIB-specific antibodies and methods for their use
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
WO2008007941A1 (en) * 2006-07-10 2008-01-17 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Gainac specific binding molecules and uses thereof
US8337852B2 (en) * 2006-08-22 2012-12-25 G2 Inflammation Pty Ltd Anti-C5aR antibodies with improved properties
ES2620261T3 (es) 2006-09-10 2017-06-28 Glycotope Gmbh Uso de células humanas de origen leucémico mieloide para expresión de anticuerpos
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
US8795667B2 (en) 2007-12-19 2014-08-05 Macrogenics, Inc. Compositions for the prevention and treatment of smallpox
AU2008343855B2 (en) 2007-12-21 2013-08-15 Amgen Inc. Anti-amyloid antibodies and uses thereof
US8669349B2 (en) 2008-04-02 2014-03-11 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
JP5555223B2 (ja) 2008-04-02 2014-07-23 マクロジェニクス，インコーポレーテッド ＨＥＲ２／ｎｅｕ特異的抗体およびその使用方法
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
JP5773352B2 (ja) * 2008-10-28 2015-09-02 塩野義製薬株式会社 抗ｍｕｃ１抗体
EP2281844A1 (en) * 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
KR20150089096A (ko) * 2009-08-17 2015-08-04 트라콘 파마수티칼즈, 인코포레이티드 항엔도글린 항체 및 항ｖｅｇｆ 제제를 사용한 암 치료를 위한 병용 요법
US8221753B2 (en) * 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
ES2672121T3 (es) 2009-10-07 2018-06-12 Macrogenics, Inc. Polipéptidos que contienen región Fc que presentan una función efectora mejorada debido a alteraciones del grado de fucosilación, y métodos para su uso
US8518405B2 (en) * 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
US8883977B2 (en) 2010-04-28 2014-11-11 Shionogi & Co., Ltd. MUC1 antibody
AU2011286024B2 (en) 2010-08-02 2014-08-07 Macrogenics, Inc. Covalent diabodies and uses thereof
PT2603528T (pt) 2010-08-10 2016-12-01 Glycotope Gmbh Anticorpos glicosilados em fab
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
CA2836873C (en) 2011-05-21 2019-10-22 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
MX356517B (es) 2011-06-28 2018-06-01 Inhibrx Llc Polipéptidos de fusión de serpina y métodos de uso de los mismos.
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
JP2014528913A (ja) * 2011-06-28 2014-10-30 インヒブルクス リミティド ライアビリティ カンパニー Ｗａｐドメイン融合ポリペプチド及びその使用方法
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
BR112015022790A8 (pt) 2013-03-14 2020-01-21 Univ Duke molécula biespecífica, composição farmacêutica, método de tratamento de uma infecção por vírus latente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus persistente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus inativo em um indivíduo em necessidade de tal tratamento, método para exterminar uma célula que contém um genoma viral, e, método para exterminar uma célula que expressa uma proteína viral
US9587032B2 (en) * 2013-06-12 2017-03-07 The Board Of Trustees Of The Leland Stanford Junior University IgE antibodies for the inhibition of tumor metastasis
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
CA2921999C (en) 2013-09-13 2023-03-21 Genentech, Inc. Methods and compositions comprising an anti-il13 antibody and residual hamster phospholipase b-like 2
WO2015038884A2 (en) 2013-09-13 2015-03-19 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
EP3150634B1 (en) 2014-04-28 2020-04-22 Medicinal Chemistry Pharmaceuticals Co., Ltd. Anti-muc1 antibody or antigen-binding fragment thereof, and uses thereof
WO2016026143A1 (en) 2014-08-22 2016-02-25 Huiru Wang Saccharide-based biomarkers and therapeutics
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
AU2015323860B2 (en) 2014-09-29 2021-05-27 Duke University Bispecific molecules comprising an HIV-1 envelope targeting arm
CA2966905A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US11933786B2 (en) 2015-03-30 2024-03-19 Stcube, Inc. Antibodies specific to glycosylated PD-L1 and methods of use thereof
CN109152798B (zh) 2015-12-02 2022-10-21 斯特库比股份有限公司 特异于糖基化的pd-1的抗体及其使用方法
WO2017139975A1 (en) 2016-02-19 2017-08-24 Huiru Wang Antibodies against n-acetylglucosamine and n-acetyl-galactosamine
WO2017172517A1 (en) * 2016-03-29 2017-10-05 Stcube & Co., Inc. Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
US10961311B2 (en) 2016-04-15 2021-03-30 Macrogenics, Inc. B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof
EP3543337B1 (en) 2016-11-18 2022-04-20 Astellas Pharma Inc. Novel anti-human muc1 antibody fab fragment
CN110382541A (zh) 2017-03-29 2019-10-25 葛莱高托普有限公司 人源化抗cd40抗体
US20200131275A1 (en) * 2017-03-29 2020-04-30 Glycotope Gmbh Multispecific antibody constructs binding to muc1 and cd3
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
US11161911B2 (en) 2017-10-23 2021-11-02 Go Therapeutics, Inc. Anti-glyco-MUC1 antibodies and their uses
EP3700936A4 (en) * 2017-10-24 2021-05-26 Go Therapeutics, Inc. ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES
BR112020015202A2 (pt) 2018-03-01 2020-12-29 Glycotope Gmbh Construções de proteínas de fusão compreendendo um anticorpo anti-muc1 e il-15
US20210221910A1 (en) 2018-05-18 2021-07-22 Glycotope Gmbh Anti-muc1 antibody
KR102463078B1 (ko) * 2022-01-24 2022-11-03 싸이런테라퓨틱스 주식회사 Muc-1에 특이적으로 결합하는 항체 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329004A (en) * 1980-05-12 1982-05-11 Litton Systems, Inc. Gas filled high voltage slip ring assembly
US5683674A (en) 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
WO1993020841A1 (en) 1992-04-13 1993-10-28 Dana-Farber Cancer Institute, Inc. Antibodies specific for carcinoma-associated antigens
US5804187A (en) 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
DE4329004A1 (de) 1993-08-28 1995-03-09 Max Delbrueck Centrum Monoklonale Antikörper gegen das Thomsen-Friedenreich-Antigen, ihre Herstellung und ihre Verwendung zum Tumornachweis
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
AU782569B2 (en) 1999-08-18 2005-08-11 Oncoquest Inc. Therapeutic binding agents against MUC-1 antigen and methods of their use
US7147850B2 (en) * 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
US20020146750A1 (en) * 2000-03-30 2002-10-10 Hoogenboom Hendricus R.J.M. Mucin-1 specific binding members and methods of use thereof
GB0029360D0 (en) * 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
DE10303664A1 (de) * 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren

Also Published As

Publication number Publication date
PT2053063E (pt) 2013-09-24
SI2053063T1 (sl) 2013-10-30
ES2321298T3 (es) 2009-06-04
WO2004065423A3 (de) 2004-11-25
WO2004065423A2 (de) 2004-08-05
EP2053063A1 (de) 2009-04-29
US9845361B2 (en) 2017-12-19
PT1585770E (pt) 2009-03-18
SI1585770T1 (sl) 2009-06-30
CY1108965T1 (el) 2014-07-02
ES2427832T3 (es) 2013-11-04
US20150005474A1 (en) 2015-01-01
DK1585770T3 (da) 2009-05-04
US8779102B2 (en) 2014-07-15
EP1585770A2 (de) 2005-10-19
DE502004008910D1 (de) 2009-03-12
DE10303664A1 (de) 2004-08-12
CY1114409T1 (el) 2016-08-31
ATE421537T1 (de) 2009-02-15
EP1585770B1 (de) 2009-01-21
US20060292643A1 (en) 2006-12-28
EP2053063B1 (de) 2013-06-19

Similar Documents

Publication Publication Date Title
DK2053063T3 (da) Genkendelsesmolekyler til behandling og påvisning af tumorer
DE602005016712D1 (de) Rter dna
CY1115859T1 (el) Ειδικα εναντι ογκων μορια αναγνωρισης
NO20082559L (no) Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer
BRPI0315666B8 (pt) dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
Sharathchandra et al. IRES mediated translational regulation of p53 isoforms
WO2005077091A3 (en) Nicotinamide riboside kinase compositions and methods for using the same
WO2006116322A3 (en) Nicotinamide riboside kinase compositions and methods for using the same
JP2005522999A5 (da)
ZA200610470B (en) Novel sequence for improving expression of nucleic acid
ATE488591T1 (de) Neuer l-lysin-induzierbarer promotor
RS92704A (en) Immunoglobulin-domain containing cell surface recognition molecules
BR0116763A (pt) Anticorpos humanos especìficos para terapia seletiva do c ncer
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
SE0301987D0 (sv) New polypeptide
CY1110308T1 (el) Μοριο νουκλεϊνικου οξεος, το οποιο περιλαμβανει μια κωδικευσουσα για αιμοκυανινη ακολουθια νουκλεϊνικου οξεος και τουλαχιστον μια ακολουθια ιντρονιου
WO2006020824A3 (en) Diagnosis and treatment of kawasaki disease and coronavirus infection
WO2004078097A8 (en) Modified aerolysin linked to a lung cancer binding agent and methods of use for treating lung cancer
WO2000055192A3 (de) Hämocyanin und dafür kodierende nukleinsäuresequenz
WO2006057917A3 (en) Hemipteran 5ht1 receptor
EP1524275A3 (en) Deimmunized binding molecules to CD3
WO2002036620A3 (en) Ets-transcription factor related compound specific promoter and transactivators thereof
EP1482038A4 (en) NOVEL PROTEIN AND DNA THEREOF
WO2004015127A3 (en) Anticodon-based libraries and molecules for the specific shotgun and/or direct targeting of, and/or interaction with cells, tissues, surfaces, materials, molecules, and energy fields